Onchilles Pharma Inc

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Neutrophil elastase (ELANE) pathway - N17350 acts as a direct protease/enzyme therapeutic rather than a receptor-binding inhibitorBiologic (subtype unspecified)
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
N17350Phase 1/2Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck Neoplasms, Carcinoma …
Est. primary completion 2028-07 · NCT07339176 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.